Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 147468, 12 pages
http://dx.doi.org/10.1155/2015/147468
Research Article

RLN2 Is a Positive Regulator of AKT-2-Induced Gene Expression Required for Osteosarcoma Cells Invasion and Chemoresistance

1Department of Spine, The Affiliated Hospital of Qingdao University, Qingdao, China
2Department of Orthopedics, Linyi People’s Hospital, Linyi, Shandong, China
3Department of Dialysis Room, Zhangqiu Hospital of Traditional Chinese Medicine, Zhangqiu, Jinan, China
4Department of Neurology, People’s Hospital of Zhangqiu, Jinan, China

Received 4 April 2015; Revised 9 June 2015; Accepted 11 June 2015

Academic Editor: John D. Wade

Copyright © 2015 Jinfeng Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Mirabello, R. J. Troisi, and S. A. Savage, “Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program,” Cancer, vol. 115, no. 7, pp. 1531–1543, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Akiyama, C. R. Dass, and P. F. M. Choong, “Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway,” Molecular Cancer Therapeutics, vol. 7, no. 11, pp. 3461–3469, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Ma, M. Niu, W. Yang, L. Zang, and Y. Xi, “Role of relaxin-2 in human primary osteosarcoma,” Cancer Cell International, vol. 13, article 59, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. M. A. Huber, N. Azoitei, B. Baumann et al., “NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression,” Journal of Clinical Investigation, vol. 114, no. 4, pp. 569–581, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. D. S. Bassères and A. S. Baldwin, “Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression,” Oncogene, vol. 25, no. 51, pp. 6817–6830, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Hotfilder, P. Sondermann, A. Senß, F. van Valen, H. Jürgens, and J. Vormoor, “PI3K/AKT is involved in mediating survival signals that rescue Ewing tumour cells from fibroblast growth factor 2-induced cell death,” British Journal of Cancer, vol. 92, no. 4, pp. 705–710, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Fukaya, N. Ishiguro, T. Senga et al., “A role for PI3K-Akt signaling in pulmonary metastatic nodule formation of the osteosarcoma cell line, LM8,” Oncology Reports, vol. 14, no. 4, pp. 847–852, 2005. View at Google Scholar · View at Scopus
  8. Y. Zhu, J. Zhou, Y. Ji, and B. Yu, “Elevated expression of AKT2 correlates with disease severity and poor prognosis in human osteosarcoma,” Molecular Medicine Reports, vol. 10, no. 2, pp. 737–742, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Sancéau, D. D. Boyd, M. Seiki, and B. Bauvois, “Interferons inhibit tumor necrosis factor-α-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-κB,” Journal of Biological Chemistry, vol. 277, no. 38, pp. 35766–35775, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. C.-Y. Huang, C.-Y. Lee, M.-Y. Chen et al., “Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-κB-dependent pathways,” Journal of Cellular Physiology, vol. 221, no. 1, pp. 204–212, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Bialek, U. Kunanuvat, S. Hombach-Klonisch et al., “Relaxin enhances the collagenolytic activity and in vitro invasiveness by upregulating matrix metalloproteinases in human thyroid carcinoma cells,” Molecular Cancer Research, vol. 9, no. 6, pp. 673–687, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Xiao, Y. Tang, Y.-L. Wang et al., “ART1 silencing enhances apoptosis of mouse CT26 cells via the PI3K/Akt/NF-κB pathway,” Cellular Physiology and Biochemistry, vol. 32, no. 6, pp. 1587–1599, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Jia, L.-J. Heng, R.-H. Yang, and G.-D. Gao, “Fish oil improves learning impairments of diabetic rats by blocking PI3K/AKT/nuclear factor-κB-mediated inflammatory pathways,” Neuroscience, vol. 258, pp. 228–237, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Kaur, N. Sharma, S. R. Krishn et al., “MUC4-mediated regulation of acute phase protein lipocalin 2 through HER2/AKT/NF-κB signaling in pancreatic cancer,” Clinical Cancer Research, vol. 20, no. 3, pp. 688–700, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Song, W. Ge, H. Cai, and H. Zhang, “Curcumin protects mice from coxsackievirus B3-induced myocarditis by inhibiting the phosphatidylinositol 3 kinase/Akt/nuclear factor-κB pathway,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 18, no. 6, pp. 560–569, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Inoue, N.-A. Matsuki, G. Jing, T. Kanematsu, K. Abe, and M. Hirata, “The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFκB pathway in osteosarcoma cells,” British Journal of Pharmacology, vol. 146, no. 5, pp. 633–641, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. L. B. Zhu, J. Jiang, X. P. Zhu et al., “Knockdown of Aurora-B inhibits osteosarcoma cell invasion and migration via modulating PI3K/Akt/NF-κB signaling pathway,” International Journal of Clinical and Experimental Pathology, vol. 7, no. 7, pp. 3984–3991, 2014. View at Google Scholar · View at Scopus
  18. E. K. Jeong, S. Y. Lee, H. M. Jeon, M. K. Ju, C. H. Kim, and H. S. Kang, “Role of extracellular signal-regulated kinase (ERK)1/2 in multicellular resistance to docetaxel in MCF-7 cells,” International Journal of Oncology, vol. 37, no. 3, pp. 655–661, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Mirmohammadsadegh, R. Mota, A. Gustrau et al., “ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis,” Journal of Investigative Dermatology, vol. 127, no. 9, pp. 2207–2215, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Yoon, J.-K. Min, J. W. Lee, D.-G. Kim, and H. J. Hong, “Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2,” Biochemical and Biophysical Research Communications, vol. 405, no. 3, pp. 333–337, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Zheng, X. Jiao, Y. Jiang, and S. Sun, “ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells,” Journal of International Medical Research, vol. 41, no. 2, pp. 300–360, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Si, C. Peng, J. Li et al., “RNAi-mediated knockdown of ERK1/2 inhibits cell proliferation and invasion and increases chemosensitivity to cisplatin in human osteosarcoma U2-OS cells in vitro,” International Journal of Oncology, vol. 40, no. 4, pp. 1291–1297, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Wang, Y. Zhuang, C. Liu, and Y. Li, “Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling,” Archives of Biochemistry and Biophysics, vol. 526, no. 1, pp. 38–43, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Zhang, M. Li, X. Zhu, Y. Bai, and C. Yang, “Knockdown of Akt sensitizes osteosarcoma cells to apoptosis induced by cisplatin treatment,” International Journal of Molecular Sciences, vol. 12, no. 5, pp. 2994–3005, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. B. N. Fahy, M. Schlieman, S. Virudachalam, and R. J. Bold, “AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2,” British Journal of Cancer, vol. 89, no. 2, pp. 391–397, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Chen, M. Niu, X. Jiao, K. Zhang, J. Liang, and D. Zhang, “Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma,” International Journal of Molecular Sciences, vol. 13, no. 1, pp. 1186–1208, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Zhang, Z.-L. Shi, B. Liu, X.-B. Yan, J. Feng, and H.-M. Tao, “Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-kappaB,” Anti-Cancer Drugs, vol. 21, no. 3, pp. 288–296, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Neschadim, L. B. Pritzker, K. P. H. Pritzker et al., “Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts,” Endocrine-Related Cancer, vol. 21, no. 3, pp. 459–471, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. Q. Zhang, S.-H. Liu, M. Erikson, M. Lewis, and D. E. Unemori, “Relaxin activates the MAP kinase pathway in human endometrial stromal cells,” Journal of Cellular Biochemistry, vol. 85, no. 3, pp. 536–544, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Feng, I. U. Agoulnik, N. V. Bogatcheva et al., “Relaxin promotes prostate cancer progression,” Clinical Cancer Research, vol. 13, no. 6, pp. 1695–1702, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Shabanpoor, F. Separovic, and J. D. Wade, “The human insulin superfamily of polypeptide hormones,” Vitamins and Hormones, vol. 80, pp. 1–31, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Y. Hsu, K. Nakabayashi, S. Nishi et al., “Activation of orphan receptors by the hormone relaxin,” Science, vol. 295, no. 5555, pp. 671–674, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Kumagai, S. Y. Hsu, H. Matsumi et al., “INSL3/Leydig insulin-like peptide activates the LGR8 receptor important in testis descent,” The Journal of Biological Chemistry, vol. 277, no. 35, pp. 31283–31286, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. O. Bartsch, B. Bartlick, and R. Ivell, “Relaxin signalling links tyrosine phosphorylation to phosphodiesterase and adenylyl cyclase activity,” Molecular Human Reproduction, vol. 7, no. 9, pp. 799–809, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. O. Bartsch, B. Bartlick, and R. Ivell, “Phosphodiesterase 4 inhibition synergizes with relaxin signaling to promote decidualization of human endometrial stromal cells,” The Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 1, pp. 324–334, 2004. View at Publisher · View at Google Scholar
  36. E. N. Unemori, M. Lewis, J. Constant et al., “Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites,” Wound Repair and Regeneration, vol. 8, no. 5, pp. 361–370, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. J. D. Silvertown, J. Ng, T. Sato, A. J. Summerlee, and J. A. Medin, “H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis,” International Journal of Cancer, vol. 118, no. 1, pp. 62–73, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. I. Pal and M. Mandal, “PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes,” Acta Pharmacologica Sinica, vol. 33, no. 12, pp. 1441–1458, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. J.-E. Kurtz and I. Ray-Coquard, “PI3 kinase inhibitors in the clinic: an update,” Anticancer Research, vol. 32, no. 7, pp. 2463–2470, 2012. View at Google Scholar · View at Scopus
  40. J. Karar and A. Maity, “PI3K/AKT/mTOR pathway in angiogenesis,” Frontiers in Molecular Neuroscience, vol. 4, article 51, 2011. View at Publisher · View at Google Scholar
  41. M. Falasca, “PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs,” Current Pharmaceutical Design, vol. 16, no. 12, pp. 1410–1416, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Astuti, K. Nakabayashi, M. Deguchi, Y. Ebina, and H. Yamada, “Human recombinant H2 relaxin induces AKT and GSK3β phosphorylation and HTR-8/SVneo cell proliferation,” Kobe Journal of Medical Sciences, vol. 61, no. 1, pp. E1–E8, 2015. View at Google Scholar
  43. N. Ahmad, W. Wang, R. Nair, and S. Kapila, “Relaxin induces matrix-metalloproteinases-9 and -13 via RXFP1: induction of MMP-9 involves the PI3K, ERK, Akt and PKC-ζ pathways,” Molecular and Cellular Endocrinology, vol. 363, pp. 46–61, 2012. View at Google Scholar
  44. R. Kumar, S. S. Sankineani, S. Rastogi et al., “Expression of Vascular endothelial growth factor in Ewing's sarcoma,” International Orthopaedics, vol. 36, no. 8, pp. 1669–1672, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Yin, T. Jia, W. Gong et al., “VEGF blockade decelerates the growth of a murine experimental osteosarcoma,” International Journal of Oncology, vol. 33, no. 2, pp. 253–259, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Mei, Y. Gao, L. Zhang et al., “VEGF-siRNA silencing induces apoptosis, inhibits proliferation and suppresses vasculogenic mimicry in osteosarcoma in vitro,” Experimental Oncology, vol. 30, no. 1, pp. 29–34, 2008. View at Google Scholar · View at Scopus
  47. B. P. Himelstein, N. Asada, M. R. Carlton, and M. H. Collins, “Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma,” Medical and Pediatric Oncology, vol. 31, no. 6, pp. 471–474, 1998. View at Google Scholar · View at Scopus
  48. K. Bjørnland, K. Flatmark, S. Pettersen, A. O. Aaasen, Ø. Fodstad, and G. M. Mælandsmo, “Matrix metalloproteinases participate in osteosarcoma invasion,” Journal of Surgical Research, vol. 127, no. 2, pp. 151–156, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Sancéau, S. Truchet, and B. Bauvois, “Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing's sarcoma cells,” The Journal of Biological Chemistry, vol. 278, no. 38, pp. 36537–36546, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Dell'Eva, C. Ambrosini, N. Vannini, G. Piaggio, A. Albini, and N. Ferrari, “AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies,” Cancer, vol. 110, no. 9, pp. 2007–2011, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. Q. Tong, L. Zheng, L. Lin et al., “VEGF is upregulated by hypoxia-induced mitogenic factor via the PI-3K/Akt-NF-kappaB signaling pathway,” Respiratory Research, vol. 7, article 37, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. M. W. Mayo, C. E. Denlinger, R. M. Broad et al., “Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-κB through the Akt pathway,” The Journal of Biological Chemistry, vol. 278, no. 21, pp. 18980–18989, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. A.-K. Dilly, P. Ekambaram, Y. Guo et al., “Platelet-type 12-lipoxygenase induces MMP9 expression and cellular invasion via activation of PI3K/Akt/NF-κB,” International Journal of Cancer, vol. 133, no. 8, pp. 1784–1791, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. W. Li, J. Ma, Q. Ma et al., “Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway,” Current Medicinal Chemistry, vol. 20, no. 33, pp. 4185–4194, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. Z. Ding, F. Xu, G. Li et al., “Knockdown of Akt2 expression by shRNA inhibits proliferation, enhances apoptosis, and increases chemosensitivity to paclitaxel in human colorectal cancer cells,” Cell Biochemistry and Biophysics, vol. 71, no. 1, pp. 383–388, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. L.-L. Zhang, J. Zhang, L. Shen, X.-M. Xu, and H.-G. Yu, “Overexpression of AKT decreases the chemosensitivity of gastric cancer cells to cisplatin in vitro and in vivo,” Molecular Medicine Reports, vol. 7, no. 5, pp. 1387–1390, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. G. Zhao, C. Cai, T. Yang et al., “MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma,” PLoS ONE, vol. 8, Article ID e53906, 2013. View at Google Scholar
  58. Y. Chen, Z. Wang, P. Chang et al., “The effect of focal adhesion kinase gene silencing on 5-fluorouracil chemosensitivity involves an Akt/NF-κB signaling pathway in colorectal carcinomas,” International Journal of Cancer, vol. 127, no. 1, pp. 195–206, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. Z. Y. Fu, J. H. Lv, C. Y. Ma, D. P. Yang, and T. Wang, “Tissue inhibitor of metalloproteinase-1 decreased chemosensitivity of MDA-435 breast cancer cells to chemotherapeutic drugs through the PI3K/AKT/NF-кB pathway,” Biomedicine and Pharmacotherapy, vol. 65, no. 3, pp. 163–167, 2011. View at Publisher · View at Google Scholar · View at Scopus